Bikash was the CMO for Aurora from March 2016 to September 2016. He is currently Head, Clinical Development & Medical Affairs at Celyad. Bikash is a physician-scientist trained in immunology and immuno-oncology with over two decades of experience in clinical research and development both in biotech industry and academia. Prior to joining Aurora, he worked as medical director at GSK and Novartis managing over twenty trials in immunology encompassing over ten thousand subjects across more than a hundred clinical trial sites in US and abroad leading to successful licensure of several products. Prior to joining the biotech industry, he worked at Harvard Medical School as medical director, faculty and scientist; and in public health and clinical care as an Epidemiologist through Massachusetts Department of Public Health on Centers of Disease Control (CDC) surveillance projects and at International Health Organization as its Chief Medical Officer. Bikash holds MD, DVM, MS and MVSc degress and post-doctoral trainings which he completed at University of Massachusetts Medical School and its affiliated hospitals, University of Illinois, S Illinois University, Birsa University, International School of Medicine, and Tufts University.
Patrick Wen is Director of the Center For Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. Dr. Wen is also chair of the Dana-Farber/Harvard Cancer Center Neuro-Oncology Clinical Trials Committee and principal or co-investigator of many ongoing clinical protocols. Dr. Wen's clinical research focuses on targeted molecular therapies and anti-angiogenic therapies for gliomas, meningiomas, and brain metastases. He serves on numerous national and international committees, including the NCI Developmental Therapeutics and the Cancer Diagnostic and Treatment SBIR Study Sections and co-chairs the American Brain Tumor Consortium New Agents Committees. He is Editor-in-Chief for the Journal of Neuro-Oncology and on the editorial board of Clinical Cancer Research. He is Chair of the Medical Advisory Board for the National Brain Tumor Society.
Kevin Krenitsky is a corporate strategist, and turnaround expert with significant experience growing and transforming venture-capital startup, privately held, and publicly traded organizations. Dr. Krenitsky has served as President at OpGen. At Foundation Medicine, Dr. Krenitsky was influential in taking the company from start-up to a $1 billion IPO in 2 years and later a 1.2B strategic investment by Roche. Dr. Krenitsky was also responsible for leading one of the most successful commercial launches (FoundationOne™) in the history of molecular diagnostics. Dr. Krenitsky has achieved a Doctor of Medicine degree from Jefferson Medical College in Philadelphia, PA, a Bachelor of Science degree in Business Management from the University of Scranton, PA, and is a Licensed Medical Doctor in the Commonwealth of Pennsylvania & Massachusetts.